Nascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.